Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

By Charlie Conchie LONDON (Reuters) -AstraZeneca’s move to upgrade its listing in the U.S. risks pulling liquidity away from ...

AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients at a discount of up ...

The PPD™ clinical research business of Thermo Fisher Scientific, the world leader in serving science, today announced a new ...

AstraZeneca is the latest big pharma group to open up a Direct-To-Consumer (DTC) sales channel in the US, offering three of ...

AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for ...

AstraZeneca is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust ...

AstraZeneca plans to list its shares in New York while keeping its London listing, a move that could allow easier access to ...

The FTSE 100 rose 1.1% to close at another record, posting its best day since July 10 thanks to a surge in pharmaceutical ...

AstraZeneca aims to harmonize its share listings globally to enhance sustainable growth and investor reach, maintaining headquarters in the UK. Enhertu shows superior outcomes in early-stage ...

AstraZeneca has asked the Supreme Court to hear its case challenging the Medicare Drug Price Negotiation Program created ...